Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ANCRE)
A Study on the Safety and Efficacy of Adalimumab Combined With Chemoradiotherapy as Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Baisheng Chen, M.D, PhD
- Telefonnummer: +86-13560471611
- E-mail: Pason06213367@163.com
Studiesteder
-
-
Guangdong
-
Guangzhou, Guangdong, Kina
- Rekruttering
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
-
Kontakt:
- Baisheng Chen Chen
- Telefonnummer: +86-13560471611
- E-mail: Pason06213367@163.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- - 1. Provided informed consent and sign the informed consent form;
- 2. Male or female, Aged 18-75 years (counted on the date of signing informed consent);
- 3. Pathological confirmed ESCC;
- 4. Patients assessed by thoracic oncologists as resectable without distant metastasis
- 5. Patients evaluate with clinical staging of T1-4aN1-3M0 or T3-4aN0M0(AJCC 9.0) based on imaging and pathological examination results;
- 6. Have at least one assessable lesion according to the RECIST V1.1
- 7. ECOG-PS score: 0-1;
- 8. Patients with normal function of organs such as heart, brain, lungs, and kidneys who can tolerate surgery;
- 9. With a life expectancy of ≥ 6 weeks;
- 10. Adequate major organ function without severe hematologic, cardiac, pulmonary, hepatic, renal, or bone marrow dysfunction, and no immunodeficiency disease;
Exclusion Criteria:
- 1. Patients who have received or are currently receiving chemotherapy, radiotherapy, immunotherapy, or targeted therapy
- 2. Patients with distant metastasis or inability to undergo resection after evaluation by thoracic surgeons
- 3. Simultaneously developing tumors in other parts of the body
- 4. Severe impairment of heart, liver, and kidney function (heart function grade 3-4, ALT and/or AST exceeding the upper limit of normal by more than 1.5 times, Cr (serum creatinine) exceeding the upper limit of normal by more than 1.5 times)
- 5. Patients with a history of autoimmune diseases who were receiving immunosuppressive therapy prior to enrollment, with immunosuppressive doses>10 mg/day or oral prednisone for more than 2 weeks
- 6. Severe allergy to immune preparations
- 7. Abnormal coagulation function: (PT>16s, APTT>53s, TT>21s, Fib<1.5 g/L), bleeding tendency or during thrombolytic or anticoagulant therapy
- 8. Pregnancy or lactation period
- 9. Other situations as judged by investigators not suitable for inclusion.;
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Adebrelimab and nab-paclitaxel plus carboplatin followed by radiotherapy
Patients would receive Adebrelimab (IV 1200mg d1) and nab-paclitaxel (IV 220 mg/m²d1) plus carboplatin (AUC = 5, d1) for two 21-day cycles, followed by one week off for radiotherapy (2.5 ⨉12 Gy).
After radiotherapy, another cycle of Adebrelimab (IV 1200mg d1) would be given.
4 to 6 weeks after completing the neoadjuvant therapy, patients would undergo esophagectomy.
|
Patients would receive Adebrelimab (IV 1200mg d1) and nab-paclitaxel (IV 220 mg/m²d1) plus carboplatin (AUC = 5, d1) for two 21-day cycles, followed by one week off for radiotherapy (2.5 ⨉12 Gy).
After radiotherapy, another cycle of Adebrelimab (IV 1200mg d1) would be given.
4 to 6 weeks after completing the neoadjuvant therapy, patients would undergo esophagectomy.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Pathological complete response (pCR)
Tidsramme: From patient enrollment to the end of surgery
|
The proportion of subjects with no residual viable tumor cells(ypT0N0) in the primary tumor and lymph nodes; that is, the proportion of patients who have achieved complete remission among PPS(Per-Protocol Set).
|
From patient enrollment to the end of surgery
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
R0 resection rate
Tidsramme: From patient enrollment to the end of surgery
|
The proportion of patients with tumor margins showing no residual cancer cells under the microscope after surgical resection.
That is, the proportion of patients in PPS achieving R0 resection.
|
From patient enrollment to the end of surgery
|
|
Disease free survival (DFS)
Tidsramme: up to 24 months post-surgery
|
Disease free survival (DFS) refers to the time from the start of treatment until disease recurrence or death from any cause, whichever occurs first.
|
up to 24 months post-surgery
|
|
Overall survival (OS)
Tidsramme: up to 24 months after surgery
|
OS is the time interval from the start of treatment to death due to any reason or loss of follow-up
|
up to 24 months after surgery
|
|
Major pathological remission (MPR)
Tidsramme: From patient enrollment to the end of surgery
|
Major pathological remission (MPR) refers to the percentage of residual tumor cells in the tumor bed after neoadjuvant therapy being ≤ 10%, regardless of whether there are residual tumor cells in the lymph nodes.
|
From patient enrollment to the end of surgery
|
|
Progression free survival (PFS)
Tidsramme: Up to 24 months post-surgery
|
PFS is defined as the time from the start of treatment to the date of first documentation of disease progression, or date of death, whichever occurred first.
|
Up to 24 months post-surgery
|
|
Event free survival (EFS)
Tidsramme: From patient enrollment to the end of surgery
|
EFS refers to the time from the start of treatment to the occurrence of any event, including disease progression, cessation of treatment for any reason, or death.
|
From patient enrollment to the end of surgery
|
|
Adverse Events
Tidsramme: from the first drug administration to within 30 days for the last Adebrelimab dose
|
Number of adverse events.
The evaluation criteria for adverse reactions are based on the American Cancer Institute Common Adverse Event Terminology 4.0 (CTCAE 5.0) and the Acute Radiation Injury Grading Standards of the American Oncology Radiotherapy Collaboration Group (RTOG).
|
from the first drug administration to within 30 days for the last Adebrelimab dose
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer efter sted
- Neoplasmer
- Neoplasmer efter histologisk type
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Gastrointestinale sygdomme
- Neoplasmer i hoved og hals
- Neoplasmer, kirtel og epitel
- Esophageale sygdomme
- Karcinom
- Neoplasmer, pladecelle
- Karcinom, pladecelle
- Esophageale neoplasmer
- Esophageal pladecellekarcinom
- Organiske kemikalier
- Terapeutik
- Koordinationskomplekser
- Carboplatin
- Strålebehandling
- 130-nm albuminbundet paclitaxel
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- SYSKY-2025-799-02
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .